entertainment -WSS

entertainment

author：hotspot 2025-08-28 08:40:01 - browse：9

Stephen Quake: "Our North Star for the next decade is understanding the mysteries of the cell." Chan Zuckerberg Initiative

SAN DIEGO — Decades ago, as a young physics Ph.D. student, Stephen Quake stumbled into the messy, dazzlingly complicated world of biology — and he’s stayed there ever since.

Quake, a professor of bioengineering and applied physics at Stanford, is a prolific academic whose discoveries have fueled the field of blood-based prenatal testing and the use of microfluidic chips, which allow scientists to quickly analyze DNA, RNA, proteins, and cells. He’s also head of science for the Chan Zuckerberg Initiative, or CZI, a company Mark Zuckerberg and Priscilla Chan founded in 2015 with the expressed intent to help “cure, prevent or manage all diseases by the end of this century.” The organization funds academic research and operates three biohubs in San Francisco, Chicago, and New York, each centered on goals such as building cells that can survey the body for signs of disease or deciphering the signals that drive inflammatory disease.

STAT sat down with Quake in front of an audience during the annual meeting of the Biotechnology Innovation Organization for a fireside chat about his pivot into the life sciences — and his second unexpected journey into the world of philanthropy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： How to convince healthy people to buy insurance

WSS

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Travis Kelce and the trap of celebrity vaccine endorsements

Prime Medicine says its gene editing passes test in monkeys

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Private equity could exacerbate cardiology's overuse problem, experts fear

Humans aren't the only ones with an imagination. Rats have it too

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Humans aren't the only ones with an imagination. Rats have it too

Bright Health sells Medicare Advantage business to Molina

FDA proposes changes to key medical devices approval pathway

Wildfire smoke exposes gaps in outdoor worker protections

Bill would allow buprenorphine prescription for addiction via telehealth

Virginia high school admissions case could be legal follow

What is microchimerism and how does it affect maternal health?

In Memoriam: Notable people who died in 2023

All of Us, NIH's precision medicine initiative, gets a big boost

leisure time

Key Senate panel to consider PBM, drug pricing reform package

How medical schools plan to diversify without affirmative action

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Will the IRA bring competition to the biologics market?

Prime Medicine says its gene editing passes test in monkeys

focus

focus

knowledge

leisure time